A Phase 1 Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery

Trial Profile

A Phase 1 Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Sep 2017

At a glance

  • Drugs AVB 620 (Primary)
  • Indications Advanced breast cancer; Early breast cancer
  • Focus Adverse reactions; First in man
  • Sponsors Avelas BioSciences
  • Most Recent Events

    • 26 Sep 2017 Results published in Annals of Surgical Oncology, according to an Avelas BioSciences media release.
    • 08 Dec 2016 Results published in an Avelas BioSciences media release.
    • 08 Dec 2016 According to an Avelas BioSciences media release, data from the study has been presented at the San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top